Original Research

Published on 14 Nov 2023

The activity of a PI3K δ-sparing inhibitor, MEN1611, in non-small cell lung cancer cells with constitutive activation of the PI3K/AKT/mTOR pathway

in Cancer Molecular Targets and Therapeutics

Giuliana Papoff
Dario Presutti
Valentina Fustaino
Andrea Parente
Clelia Calandriello
Stefano Alemà
Ferdinando Scavizzi
Marcello Raspa
Giuseppe Merlino
Massimiliano Salerno

Frontiers in Oncology

doi 10.3389/fonc.2023.1283951

1,780 views
1 citation

Retraction

Published on 10 Nov 2023

Retraction: The oncolytic virus in cancer diagnosis and treatment

in Cancer Molecular Targets and Therapeutics

Frontiers Editorial Office

Frontiers in Oncology

doi 10.3389/fonc.2023.1320477

1,939 views

Case Report

Published on 09 Nov 2023

Case Report: A novel TP53 mutation in a patient with quadruple wild-type gastrointestinal stromal tumor

in Cancer Molecular Targets and Therapeutics

Yuhong Chen
Junyong Chen
Liansheng Long
Leng Han
Xiaohui Mi
Yanfang Song
Huanqing Cheng
Yanrui Zhang
Liyang Cheng

Frontiers in Oncology

doi 10.3389/fonc.2023.1260706

1,234 views
1 citation

Mini Review

Published on 08 Nov 2023

Targeting casein kinase 1 for cancer therapy: current strategies and future perspectives

in Cancer Molecular Targets and Therapeutics

Ngo Hoang Long
Sook-Jeong Lee

Frontiers in Oncology

doi 10.3389/fonc.2023.1244775

2,952 views
1 citation

Review

Published on 07 Nov 2023

Advances in the relationship between ferroptosis and epithelial–mesenchymal transition in cancer

in Cancer Molecular Targets and Therapeutics

Wenrong Mu
Zubang Zhou
Liping Shao
Qi Wang
Wanxue Feng
Yuling Tang
Yizong He
Yuanlin Wang

Frontiers in Oncology

doi 10.3389/fonc.2023.1257985

2,038 views

Review

Published on 07 Nov 2023

Cuproptosis: emerging biomarkers and potential therapeutics in cancers

in Cancer Molecular Targets and Therapeutics

Min Wang
Lianwen Zheng
Shuai Ma
Ruixin Lin
Jiahui Li
Shuli Yang

Frontiers in Oncology

doi 10.3389/fonc.2023.1288504

4,818 views
8 citations

Case Report

Published on 07 Nov 2023

Case Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy

in Cancer Molecular Targets and Therapeutics

Elizaveta Polyanskaya
Alexandra Lebedeva
Olesya Kuznetsova
Ekaterina Belova
Alexandra Kavun
Maxim Ivanov
Mikhail Fedyanin
Alexey Tryakin
Vladislav Mileyko
Dmitry Nosov

Frontiers in Oncology

doi 10.3389/fonc.2023.1245547

1,773 views
2 citations

Original Research

Published on 06 Nov 2023

Feasibility of apalutamide combined with androgen deprivation therapy and short-course low-dose prednisone in treating metastatic hormone-sensitive prostate cancer: a pilot randomized controlled trial

in Cancer Molecular Targets and Therapeutics

Dingyuan Yang
Wenqiang Chen
Fei Lai
Mingxing Qiu
Jun Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1110807

1,691 views

Original Research

Published on 02 Nov 2023

Discovery of potent STAT3 inhibitors using structure-based virtual screening, molecular dynamic simulation, and biological evaluation

in Cancer Molecular Targets and Therapeutics

Weifeng Liu
Zhijie Chu
Cheng Yang
Tianbao Yang
Yanhui Yang
Haigang Wu
Junjun Sun

Frontiers in Oncology

doi 10.3389/fonc.2023.1287797

2,251 views
3 citations

Original Research

Published on 02 Nov 2023

Immune signatures of the POLE mutation in endometrial carcinomas: a systematic study based on TCGA data and clinical cohort validation

in Cancer Molecular Targets and Therapeutics

Tieyan Wang
Dan Yu
Juanjuan Wang
Ningning Zhu
Xian-bin Tang
Xiuwen Chen
Xiao-min Su
Yu-gang Huang

Frontiers in Oncology

doi 10.3389/fonc.2023.1250558

2,936 views
2 citations

Original Research

Published on 30 Oct 2023

Fanconi anemia pathway regulation by FANCI in prostate cancer

in Cancer Molecular Targets and Therapeutics

Heidi Kaljunen
Sinja Taavitsainen
Roosa Kaarijärvi
Eerika Takala
Ville Paakinaho
Matti Nykter
G. Steven Bova
Kirsi Ketola

Frontiers in Oncology

doi 10.3389/fonc.2023.1260826

2,179 views
2 citations

Review

Published on 27 Oct 2023

Role and therapeutic potential of DEAD-box RNA helicase family in colorectal cancer

in Cancer Molecular Targets and Therapeutics

Bichun Zheng
Xudong Chen
Qiaoyun Ling
Quan Cheng
Shaoshun Ye

Frontiers in Oncology

doi 10.3389/fonc.2023.1278282

2,872 views

Review

Published on 26 Oct 2023

The cancer glycocode as a family of diagnostic biomarkers, exemplified by tumor-associated gangliosides

in Cancer Molecular Targets and Therapeutics

Ali Nejatie
Samantha S. Yee
Anna Jeter
Horacio Uri Saragovi

Frontiers in Oncology

doi 10.3389/fonc.2023.1261090

2,820 views
1 citation

Original Research

Published on 25 Oct 2023

Identification of prognosis-related lncRNAs and cell validation in lung squamous cell carcinoma based on TCGA data

in Cancer Molecular Targets and Therapeutics

Yishuang Cui
Yanan Wu
Mengshi Zhang
Yingze Zhu
Xin Su
Wenyue Kong
Xuan Zheng
Guogui Sun

Frontiers in Oncology

doi 10.3389/fonc.2023.1240868

1,642 views
1 citation

Review

Published on 24 Oct 2023

Lung cancer organoids: models for preclinical research and precision medicine

in Cancer Molecular Targets and Therapeutics

Yajing Liu
Yanbing Zhou
Pu Chen

Frontiers in Oncology

doi 10.3389/fonc.2023.1293441

7,493 views
5 citations

Case Report

Published on 18 Oct 2023

Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review

in Cancer Molecular Targets and Therapeutics

Yingmei Wen
Yi Dong
Lina Yi
Guifang Yang
Mengxia Xiao
Qingqing Li
Chen Zhao
Dafu Ye
Yi Yao

Frontiers in Oncology

doi 10.3389/fonc.2023.1241475

1,808 views
3 citations

Navigation group

Articles

The activity of a PI3K δ-sparing inhibitor, MEN1611, in non-small cell lung cancer cells with constitutive activation of the PI3K/AKT/mTOR pathway

Retraction: The oncolytic virus in cancer diagnosis and treatment

Case Report: A novel TP53 mutation in a patient with quadruple wild-type gastrointestinal stromal tumor

Targeting casein kinase 1 for cancer therapy: current strategies and future perspectives

Advances in the relationship between ferroptosis and epithelial–mesenchymal transition in cancer

Cuproptosis: emerging biomarkers and potential therapeutics in cancers

Case Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy

Feasibility of apalutamide combined with androgen deprivation therapy and short-course low-dose prednisone in treating metastatic hormone-sensitive prostate cancer: a pilot randomized controlled trial

Discovery of potent STAT3 inhibitors using structure-based virtual screening, molecular dynamic simulation, and biological evaluation

Immune signatures of the POLE mutation in endometrial carcinomas: a systematic study based on TCGA data and clinical cohort validation

Fanconi anemia pathway regulation by FANCI in prostate cancer

Role and therapeutic potential of DEAD-box RNA helicase family in colorectal cancer

The cancer glycocode as a family of diagnostic biomarkers, exemplified by tumor-associated gangliosides

Identification of prognosis-related lncRNAs and cell validation in lung squamous cell carcinoma based on TCGA data

Lung cancer organoids: models for preclinical research and precision medicine

Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review